Press Releases and News

RedShiftBio Appoints Topbiox as Exclusive Distributor in China Read more>

Pressure BioSciences and RedShiftBio Demonstrate Potential of Combining Proprietary Technologies to Enable New Tool for Development and Production of Biotherapeutics Read more>

RedShiftBio Appoints Julien Bradley as new CEO Read more>

RedShiftBio Expands Commercial Team to Support Demand for AQS³pro Read more>

RedShiftBio’s AQS³pro Changes the Game in the Detection and Treatment of Alzheimer’s Read more>

RedShiftBio Shipping AQS³pro as Industry Endorsements Expand Read More>

Photonics Media publishes article on Technological Synergies Move Spectroscopy Out of the Lab Read more>

RedShiftBio’s  AQS³™pro: Finalist in The Prism Awards 2019 Read more>

RedShiftBio’s AQS³pro Wins a ‘The Analytical Scientist Innovation Award’ (TASIA) 2018 Read more>

RedShiftBio to showcase successful studies with biopharma industry leaders at AAPS PharmSci 360 Read more>

Biopharm International interviews scientists with experience of Microfluidic Modulation Spectroscopy for a round-table on how complex protein studies demand dynamic techniques. Visit page 18 to see what Immunogen, Janssen, Elion Labs and the University of Delaware have to say. Read more>

American Pharmaceutical Review publishes article on MMS by Karan K. Shah Principal Development Associate Analytical and Pharmaceutical Sciences ImmunoGen, Inc. Read more>

RedShiftBio Strengthens Focus on Applications with New Hire Read more>

Spectroscopy North America publishes peer-reviewed paper on MMS from Brent Kendrick of Elion Labs, Eugene Ma and Libo Wang of RedShiftBio Read more>

RedShiftBio Expands Team to Support Launch of FlagShip AQS³™pro System for Protein Characterization Read more>

Instrument Business Outlook interviews RedShiftBio CCO Jeff Zonderman on the launch of the AQS³pro Read more>

Spectroscopy Europe highlights the launch of the AQS³pro Read more>

RedShiftBio Launches AQS³pro Protein Characterization System Read more>

RedShiftBio Announces Collaboration Trial Completion Read more>

Jeffrey Zonderman Joins RedShiftBio as its Chief Commercial Officer Read more >

RedShiftBio Inc. Completes $11.0 million Series C Financing Read more >